Olszko M E, Adair J E, Linde I, Rae D T, Trobridge P, Hocum J D, Rawlings D J, Kiem H-P, Trobridge G D
Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gene Ther. 2015 Jul;22(7):591-5. doi: 10.1038/gt.2015.20. Epub 2015 Mar 19.
Foamy virus (FV) vectors are promising for hematopoietic stem cell (HSC) gene therapy but preclinical data on the clonal composition of FV vector-transduced human repopulating cells is needed. Human CD34(+) human cord blood cells were transduced with an FV vector encoding a methylguanine methyltransferase (MGMT)P140K transgene, transplanted into immunodeficient NOD/SCID IL2Rγ(null) mice, and selected in vivo for gene-modified cells. The retroviral insertion site profile of repopulating clones was examined using modified genomic sequencing PCR. We observed polyclonal repopulation with no evidence of clonal dominance even with the use of a strong internal spleen focus forming virus promoter known to be genotoxic. Our data supports the use of FV vectors with MGMTP140K for HSC gene therapy but also suggests additional safety features should be developed and evaluated.
泡沫病毒(FV)载体在造血干细胞(HSC)基因治疗方面颇具前景,但仍需要关于FV载体转导的人类再增殖细胞克隆组成的临床前数据。用编码甲基鸟嘌呤甲基转移酶(MGMT)P140K转基因的FV载体转导人CD34(+)人脐带血细胞,将其移植到免疫缺陷的NOD/SCID IL2Rγ(null)小鼠体内,并在体内选择基因修饰细胞。使用改良的基因组测序PCR检测再增殖克隆的逆转录病毒插入位点谱。我们观察到多克隆再增殖,即使使用已知具有基因毒性的强大内部脾脏聚焦形成病毒启动子,也没有克隆优势的证据。我们的数据支持使用携带MGMTP140K的FV载体进行HSC基因治疗,但也表明应开发和评估其他安全特性。